NOD2 and glioma: Here, increased differential gene expression of MSR1, BCL10, NOD1, NOD2, NLRP12, NLRC4, TP53 and EGFR gene expression in GBM indicates altered innate immune signaling and other core cell signaling pathways in glioma pathogenesis.